GNAS1 T393C polymorphism and disease progression in patients with malignant melanoma

European Journal of Medical Research

NH Brockmeyer⁴  W Siffert²  P Altmeyer⁴  A Potthoff⁴  KW Schmid¹  S Rotterdam⁴  A Fritz⁴  UH Frey³ 

[1] Institut für Pathologie und Neuropathologie, Universität Duisburg-Essen, Universitätsklinikum Essen, Essen, Germany;Institut für Pharmakogenetik, Universität Duisburg-Essen, Universitätsklinikum Essen, Essen, Germany;Institut für Anästhesiologie und Intensivmedizin, Universität Duisburg-Essen, Universitätsklinikum Essen, Essen, Germany;Klinik für Dermatologie und Allergologie, St. Josef Hospital, Bochum, Germany

关键词: pro gnostic factor;    melanoma;    G Protein;    polymorphism;   

Others  :  829673
DOI  :  10.1186/2047-783X-15-10-422

 received in 2010-04-09, accepted in 2010-05-03,  发布年份 2010

【 摘 要 】

Background

Once metastasized, despite a variety of therapeutic options, the prognosis of patients with malignant melanoma (MM) is still poor. Therefore, the search for reliable markers to identify patients with high risk of disease progression is of high clinical importance. We have recently shown that TT genotypes of the single-nucleotide polymorphism (SNP) T393C in the gene GNAS1 are significantly associated with better outcome in a variety of carcinomas.

Patients

In the present study we assessed whether the T393C SNP is also related to the clinical course in MM. 328 patients with MM were retrospectively genotyped and genotypes were correlated with clinical outcome.

Results

While the allele frequency in the MM group (fC 0.52) did not significantly differ from that of healthy blood donors, the T393C SNP was associated with tumor progression of MM. Carriers of the C-allele showed a significantly more severe tumor progression as estimated from the time period to develop metastasis (HR 2.2, 95% CI 1.1-3.2, p = 0.017). Proportions of 5-year metastasis-free intervals were 87.1% for TT genotypes and 66.0% for C-allele carriers. Moreover, multivariable Cox regression analysis including tumor stage and melanoma subtype proved the T393C polymorphism to be an independent factor for metastasis (p = 0.012).

Conclusions

In summary, the GNAS1 T393C SNP represents a genetic host factor for predicting tumor progression also in patients with MM; genotyping of this SNP may contribute to better define patients who could benefit from an early individualized therapy.

【 授权许可】

   
2010 I. Holzapfel Publishers

【 图 表 】

Figure 1.

Figure 2.

【 参考文献 】

• [1]Rebmann V, Ugurel S, Tilgen W, et al.: Soluble HLA-DR is a potent predictive indicator of disease progression in serum from early-stage melanoma patients. Int J Cancer 2002, 100:580-5.
• [2]Bosserhoff AK, Kaufmann M, Kaluza B, et al.: Melanoma-inhibiting activity, a novel serum marker for progression of malignant melanoma. Cancer Res 1997, 57:3149-53.
• [3]Ugurel S, Rappl G, Tilgen W, et al.: Increased serum concentration of angiogenic factors in malignant melanoma patients correlates with tumor progression and survival. J Clin Oncol 2001, 19:577-83.
• [4]Ugurel S, Rappl G, Tilgen W, et al.: Increased soluble CD95 (sFas/CD95) serum level correlates with poor prognosis in melanoma patients. Clin Cancer Res 2001, 7:1282-6.
• [5]Hauschild A, Engel G, Brenner W, et al.: Predictive value of serum S100B for monitoring patients with metastatic melanoma during chemotherapy and/or immunotherapy. Br J Dermatol 1999, 140:1065-71.
• [6]Hauschild A, Engel G, Brenner W, et al.: S100B protein detection in serum is a significant prognostic factor in metastatic melanoma. Oncology 1999, 56:338-44.
• [7]Guo HB, Stoffel-Wagner B, Bierwirth T, et al.: Clinical significance of serum S100 in metastatic malignant melanoma. Eur J Cancer 1995, 31A:924-8.
• [8]Henze G, Dummer R, Joller-Jemelka HI, et al.: Serum S100--a marker for disease monitoring in metastatic melanoma. Dermatology 1997, 194:208-12.
• [9]Streit S, Mestel DS, Schmidt M, et al.: FGFR4 Arg388 allele correlates with tumour thickness and FGFR4 protein expression with survival of melanoma patients. Br J Cancer 2006, 94:1879-86.
• [10]Tsao H, Zhang X, Fowlkes K, et al.: Relative reciprocity of NRAS and PTEN/MMAC1 alterations in cutaneous melanoma cell lines. Cancer Res 2000, 60:1800-4.
• [11]Davies H, Bignell GR, Cox C, et al.: Mutations of the BRAF gene in human cancer. Nature 2002, 417:949-54.
• [12]Okamoto I, Roka F, Krogler J, et al.: The EGF A61G polymorphism is associated with disease-free period and survival in malignant melanoma. J Invest Dermatol 2006, 126:2242-6.
• [13]Frey UH, Eisenhardt A, Lummen G, et al.: The T393C polymorphism of the G alpha s gene (GNAS1) is a novel prognostic marker in bladder cancer. Cancer Epidemiol Biomarkers Prev 2005, 14:871-7.
• [14]Frey UH, Alakus H, Wohlschlaeger J, et al.: GNAS1 T393C polymorphism and survival in patients with sporadic colorectal cancer. Clin Cancer Res 2005, 11:5071-7.
• [15]Frey UH, Nuckel H, Sellmann L, et al.: The GNAS1 T393C polymorphism is associated with disease progression and survival in chronic lymphocytic leukemia. Clin Cancer Res 2006, 12:5686-92.
• [16]Frey UH, Lummen G, Jager T, et al.: The GNAS1 T393C polymorphism predicts survival in patients with clear cell renal cell carcinoma. Clin Cancer Res 2006, 12:759-63.
• [17]Daaka Y, Luttrell LM, Lefkowitz RJ: Switching of the coupling of the beta2-adrenergic receptor to different G proteins by protein kinase A. Nature 1997, 390:88-91.
• [18]Krumins AM, Barber R: Examination of the effects of increasing Gs protein on beta2-adrenergic receptor, Gs, and adenylyl cyclase interactions. Biochem Pharmacol 1997, 54:61-72.
• [19]Yang X, Lee FY, Wand GS: Increased expression of Gs(alpha) enhances activation of the adenylyl cyclase signal transduction cascade. Mol Endocrinol 1997, 11:1053-61.
• [20]Yang W, White B, Spicer EK, et al.: Complex haplotype structure of the human GNAS gene identifies a recombination hotspot centred on a single nucleotide polymorphism widely used in association studies. Pharmacogenetics 2004, 14:741-7.
• [21]Siffert W, Forster P, Jockel KH, et al.: Worldwide ethnic distribution of the G protein beta3 subunit 825T allele and its association with obesity in Caucasian, Chinese, and Black African individuals. J Am Soc Nephrol 1999, 10:1921-30.
• [22]Balch CM, Buzaid AC, Soong SJ, et al.: Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma. J Clin Oncol 2001, 19:3635-48.
• [23]Pho L, Grossman D, Leachman SA: Melanoma genetics: a review of genetic factors and clinical phenotypes in familial melanoma. Curr Opin Oncol 2006, 18:173-9.
• [24]Nikolova PN, Pawelec GP, Mihailova SM, et al.: Association of cytokine gene polymorphisms with malignant melanoma in Caucasian population. Cancer Immunol Immunother 2007, 56:371-9.
• [25]Martinez-Escribano JA, Moya-Quiles MR, Muro M, et al.: Interleukin-10, interleukin-6 and interferon-gamma gene polymorphisms in melanoma patients. Melanoma Res 2002, 12:465-9.
• [26]Buettner PG, Leiter U, Eigentler TK, et al.: Development of prognostic factors and survival in cutaneous melanoma over 25 years: an analysis of the Central Malignant Melanoma Registry of the German Dermatological Society. Cancer 2005, 103:616-24.
• [27]Duan J, Wainwright MS, Comeron JM, et al.: Synonymous mutations in the human dopamine receptor D2 (DRD2) affect mRNA stability and synthesis of the receptor. Hum Mol Genet 2003, 12:205-16.
• [28]Capon F, Allen MH, Ameen M, et al.: A synonymous SNP of the corneodesmosin gene leads to increased mRNA stability and demonstrates association with psoriasis across diverse ethnic groups. Hum Mol Genet 2004, 13:2361-8.
• [29]Tierney MJ, Medcalf RL: Plasminogen activator inhibitor type 2 contains mRNA instability elements within exon 4 of the coding region. Sequence homology to coding region instability determinants in other mRNAs. J Biol Chem 2001, 276:13675-84.
• [30]Dumaz N, Light Y, Marais R: Cyclic AMP blocks cell growth through Raf-1-dependent and Raf-1-independent mechanisms. Mol Cell Biol 2002, 22:3717-28.
• [31]Kadekaro AL, Kanto H, Kavanagh R, et al.: Significance of the melanocortin 1 receptor in regulating human melanocyte pigmentation, proliferation, and survival. Ann N Y Acad Sci 2003, 994:359-65.
• [32]Hunt G, Todd C, Cresswell JE, et al.: Alpha-melanocyte stimulating hormone and its analogue Nle4DPhe7 alpha-MSH affect morphology, tyrosinase activity and melanogenesis in cultured human melanocytes. J Cell Sci 1994, 107(Pt 1):205-11.
• [33]Dumaz N, Hayward R, Martin J, et al.: In melanoma, RAS mutations are accompanied by switching signaling from BRAF to CRAF and disrupted cyclic AMP signaling. Cancer Res 2006, 66:9483-91.
• [34]Karasarides M, Chiloeches A, Hayward R, et al.: B-RAF is a therapeutic target in melanoma. Oncogene 2004, 23:6292-8.
• [35]Hingorani SR, Jacobetz MA, Robertson GP, et al.: Suppression of BRAF(V599E) in human melanoma abrogates transformation. Cancer Res 2003, 63:5198-202.
• [36]Davies H, Bignell GR, Cox C, et al.: Mutations of the BRAF gene in human cancer. Nature 2002, 417:949-54.